A.R.T. Advisors’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

A.R.T. Advisors’s Portfolio CANF Stock Details CANF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-5	Closed	-$41K	–	702
2016 Q2	$41K	Buy	5 +1	+25%	+$8.46K	﹤0.01%	1277
2016 Q1	$35K	Buy	+4	New	+$27.7K	﹤0.01%	1298

Other funds holding CANF

TAM

Taylor Asset Management Toronto, Ontario, Canada $154M AUM 10.32% 1-Year Est. Return

Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

A.R.T. Advisors's CANF Position: Q3 2016 in Review

A.R.T. Advisors sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q3 2016, closing a stake of 5 shares — an estimated $41K sold.

A.R.T. Advisors first reported a position in CANF in Q1 2016 and held it in 2 quarters. The position peaked at $41K in Q2 2016. 5 funds tracked by Wall St. Rank hold CANF as of Q3 2016.

A.R.T. Advisors reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q3 2016 after selling out during the quarter.
A.R.T. Advisors sold 5 Can-Fite BioPharma American Depositary Shares shares in Q3 2016, an estimated $41K.
A.R.T. Advisors first reported a position in Can-Fite BioPharma American Depositary Shares in Q1 2016 and held it in 2 quarters.
A.R.T. Advisors's Can-Fite BioPharma American Depositary Shares position peaked at $41K in Q2 2016.
5 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q3 2016.

Based on A.R.T. Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.